vs
Side-by-side financial comparison of Canaan Inc. (CAN) and ENANTA PHARMACEUTICALS INC (ENTA). Click either name above to swap in a different company.
Canaan Inc. is the larger business by last-quarter revenue ($20.8M vs $18.6M, roughly 1.1× ENANTA PHARMACEUTICALS INC). Canaan Inc. runs the higher net margin — -18.4% vs -64.1%, a 45.7% gap on every dollar of revenue.
Canaan Inc., doing business as Canaan Creative and known simply as Canaan, is a Singapore-based computer hardware manufacturer. Established in 2013 by N.G. Zhang, Canaan specializes in Blockchain servers and ASIC microprocessors for use in bitcoin mining.
Enanta Pharmaceuticals Inc is a clinical-stage biotechnology company that develops innovative antiviral therapies for infectious diseases including hepatitis B virus, respiratory syncytial virus (RSV), and SARS-CoV-2. It operates primarily in the U.S. and global markets, partnering with pharmaceutical firms to advance its small molecule drug candidate pipeline for patients with unmet medical needs.
CAN vs ENTA — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $20.8M | $18.6M |
| Net Profit | $-3.8M | $-11.9M |
| Gross Margin | 99.9% | — |
| Operating Margin | -15.9% | -60.5% |
| Net Margin | -18.4% | -64.1% |
| Revenue YoY | — | 9.8% |
| Net Profit YoY | — | 46.4% |
| EPS (diluted) | $-0.05 | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $20.8M | $18.6M | ||
| Q3 25 | $13.8M | $15.1M | ||
| Q2 25 | $11.4M | $18.3M | ||
| Q1 25 | — | $14.9M | ||
| Q4 24 | — | $17.0M | ||
| Q3 24 | $10.2M | $14.6M | ||
| Q2 24 | $4.8M | $18.0M | ||
| Q1 24 | — | $17.1M |
| Q4 25 | $-3.8M | $-11.9M | ||
| Q3 25 | $-1.5M | $-18.7M | ||
| Q2 25 | $-11.9M | $-18.3M | ||
| Q1 25 | — | $-22.6M | ||
| Q4 24 | — | $-22.3M | ||
| Q3 24 | $-10.4M | $-28.8M | ||
| Q2 24 | $-5.4M | $-22.7M | ||
| Q1 24 | — | $-31.2M |
| Q4 25 | 99.9% | — | ||
| Q3 25 | 99.9% | — | ||
| Q2 25 | 99.9% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 99.9% | — | ||
| Q2 24 | 99.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | -15.9% | -60.5% | ||
| Q3 25 | -27.0% | -121.6% | ||
| Q2 25 | -45.5% | -103.2% | ||
| Q1 25 | — | -164.3% | ||
| Q4 24 | — | -138.8% | ||
| Q3 24 | -77.2% | -204.4% | ||
| Q2 24 | -193.9% | -134.6% | ||
| Q1 24 | — | -192.1% |
| Q4 25 | -18.4% | -64.1% | ||
| Q3 25 | -11.0% | -123.6% | ||
| Q2 25 | -104.4% | -99.7% | ||
| Q1 25 | — | -151.7% | ||
| Q4 24 | — | -131.4% | ||
| Q3 24 | -102.7% | -197.3% | ||
| Q2 24 | -112.3% | -126.1% | ||
| Q1 24 | — | -182.7% |
| Q4 25 | $-0.05 | $-0.42 | ||
| Q3 25 | $-0.02 | $-0.88 | ||
| Q2 25 | $-0.25 | $-0.85 | ||
| Q1 25 | — | $-1.06 | ||
| Q4 24 | — | $-1.05 | ||
| Q3 24 | — | $-1.36 | ||
| Q2 24 | — | $-1.07 | ||
| Q1 24 | — | $-1.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $37.4M |
| Total DebtLower is stronger | $6.2M | — |
| Stockholders' EquityBook value | $52.4M | $126.6M |
| Total Assets | $92.5M | $329.5M |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $37.4M | ||
| Q3 25 | — | $32.3M | ||
| Q2 25 | — | $44.8M | ||
| Q1 25 | — | $60.2M | ||
| Q4 24 | — | $84.3M | ||
| Q3 24 | — | $37.2M | ||
| Q2 24 | — | $35.8M | ||
| Q1 24 | — | $63.5M |
| Q4 25 | $6.2M | — | ||
| Q3 25 | $6.2M | — | ||
| Q2 25 | $6.2M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $52.4M | $126.6M | ||
| Q3 25 | $44.7M | $64.7M | ||
| Q2 25 | $33.8M | $79.3M | ||
| Q1 25 | — | $93.5M | ||
| Q4 24 | — | $111.8M | ||
| Q3 24 | $43.6M | $128.8M | ||
| Q2 24 | $56.8M | $148.9M | ||
| Q1 24 | — | $166.1M |
| Q4 25 | $92.5M | $329.5M | ||
| Q3 25 | $81.7M | $280.7M | ||
| Q2 25 | $78.0M | $301.0M | ||
| Q1 25 | — | $323.0M | ||
| Q4 24 | — | $348.6M | ||
| Q3 24 | $69.3M | $376.7M | ||
| Q2 24 | $73.7M | $398.8M | ||
| Q1 24 | — | $413.6M |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.14× | — | ||
| Q2 25 | 0.18× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-11.7M |
| Free Cash FlowOCF − Capex | — | $-11.8M |
| FCF MarginFCF / Revenue | — | -63.6% |
| Capex IntensityCapex / Revenue | — | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-18.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-11.7M | ||
| Q3 25 | — | $-6.5M | ||
| Q2 25 | — | $17.5M | ||
| Q1 25 | — | $-13.5M | ||
| Q4 24 | — | $-16.8M | ||
| Q3 24 | — | $-10.4M | ||
| Q2 24 | — | $-14.8M | ||
| Q1 24 | — | $-28.6M |
| Q4 25 | — | $-11.8M | ||
| Q3 25 | — | $-7.9M | ||
| Q2 25 | — | $17.4M | ||
| Q1 25 | — | $-16.0M | ||
| Q4 24 | — | $-25.5M | ||
| Q3 24 | — | $-19.4M | ||
| Q2 24 | — | $-21.3M | ||
| Q1 24 | — | $-30.3M |
| Q4 25 | — | -63.6% | ||
| Q3 25 | — | -52.5% | ||
| Q2 25 | — | 94.7% | ||
| Q1 25 | — | -107.4% | ||
| Q4 24 | — | -150.6% | ||
| Q3 24 | — | -132.5% | ||
| Q2 24 | — | -118.6% | ||
| Q1 24 | — | -177.5% |
| Q4 25 | — | 0.8% | ||
| Q3 25 | — | 9.6% | ||
| Q2 25 | — | 0.8% | ||
| Q1 25 | — | 17.0% | ||
| Q4 24 | — | 51.6% | ||
| Q3 24 | — | 61.3% | ||
| Q2 24 | — | 36.4% | ||
| Q1 24 | — | 9.8% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
